Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
29 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D2.262 - Measurement of tryptasemia in a university hospital: prescribing reality versus recommendations
D2.263 - Anaphylaxis induced by goat’s and sheep’s milk: an allergen that we should keep under surveillance
D2.264 - Food-induced Anaphylaxis: Characterization and Trends of a Four-year Single-center Survey
D2.265 - Allergy to peas and lentils: data from the Allergy-Vigilance Network
D2.266 - Four-Year Analysis of the Incidence and Clinical Features of Perioperative Hypersensitivity Reactions in the Allergy-Anaesthesia Unit, Universitary Hospital Cruz Roja
D2.267 - MiRNA-29a is downregulated in food anaphylaxis and involved in the endothelial glycocalyx stability
D2.269 - Diagnostic challenges in evaluating diagnosis of mast cell disorder in a patient with severe allergy to hymenoptera venom
D2.270 - Roadmap of anaphylaxis registries across the world
D2.271 - The non-mandatory food allergens that we should not sweep under the rug: data from the Allergy-Vigilance Network
D2.272 - Anaphylaxis caused by Psyllium
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download